Concord Drugs Ltd manufactures licensed drugs based on approved formulationsProduct Portfolio: a) Pharmaceutical Ready to fill Pellets b) Multiple Unit Pellet System (MUPS) c) Tissue Bio Adhesive d) Injectables (Small Volume Parenterals) e) Oral Solid Dosages (Tablets & Capsules) f) Liquid Orals (Syrups & Suspensions) g) Dry Syrup (Powder)
Concord Drugs has announced that its upcoming annual general meeting will take place via video conferencing, alongside temporary closures of the register of members and share transfer books for scheduling purposes. Shareholders are provided electronic voting access through a designated depository platform to cast votes ahead of the meeting. These...
Concord Drugs has announced that physical letters are being dispatched to shareholders whose email addresses are not registered, providing the web link and navigation path to access the annual report and upcoming annual general meeting details. This outreach ensures that unregistered investors can view corporate disclosures and underscores the company's...
Concord Drugs Limited has confirmed that its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, has complied with regulations concerning the dematerialization of securities for the quarter ended 30th June. This ensures that physical share certificates converted to electronic form have been correctly processed, cancelled, and recorded with depositories....
Concord Drugs Limited announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported a standalone total revenue of 78.77 Cr and a net profit of 1.05 Cr. On a consolidated basis, total revenue was 75.88 Cr, with a net profit of 1.04...
Concord Drugs Limited's Annual Secretarial Compliance Report for FY26 highlights several past compliance issues. These include a 27-day delay in submitting a regulatory report and missing mandatory disclosures on its website. Crucially, the company faced a fine of ₹0.02 Cr for not appointing a Company Secretary for two prior quarters...
